Omeros’ investigational new drug application for OMS906 cleared by FDA

This article was originally published here

OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. FDA’s clearance of the IND

The post Omeros’ investigational new drug application for OMS906 cleared by FDA appeared first on Pharmaceutical Business review.